BMS-1001 hydrochloride

Overview

BMS-1001 is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 exhibits low-toxicity in cells. The IC 50 value of BMS-1001 in a homogeneous time-resolved fluorescence (HTRF) binding assay is 2.25 nM.

Application

Products | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > PD-1/PD-L1

Product Information

• Catalog No.: HY-120635
• CAS No.: 2113650-04-5
• Molecular Formula: C35H35ClN2O7
• Molecular Weight: 631.11
• Purity: 98.01%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 1.25 mg/mL (1.98 mM); Clear solution
• Availability: In-stock

Source

Original product source